Drug Coated Balloon-Based Primary PCI in ST-segment Elevation Myocardial Infarction - The DCB-STEMI Multicenter Registry

What this Trial Is About

Researchers are investigating the use of drug-coated balloons (DCB) as a primary treatment for patients experiencing ST-segment elevation myocardial infarction (STEMI). This approach is being compared to the current standard care using drug-eluting stents (DES) in primary percutaneous coronary intervention (pPCI). The study aims to explore the safety and effectiveness of DCB-based pPCI, given its potential to reduce complications such as stent thrombosis and late adverse events, which remain concerns with traditional stenting methods. The study observes patients treated with a provisional DCB-based pPCI strategy for new coronary artery blockages. This involves using the drug-coated balloon device during the procedure without immediate stent placement, potentially simplifying the intervention and reducing risks associated with stent use. The registry collects data from patients admitted within 48 hours of symptom onset to evaluate this treatment in real-world settings. Participants are monitored for clinical outcomes including net adverse clinical events (NACE), bleeding events, and target vessel failure from January 2014 through April 2026. The study gathers procedural details and patient follow-up information over this period to assess safety and treatment success. The total participation duration varies, with data collection continuing until mid-2026 to capture both immediate and longer-term outcomes.

Drug-Coated Balloon Primary PCI in ST-Segment Elevation Myocardial Infarction